Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
LENSAR, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
08/04/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/18/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023",
"Class A Common Stock Purchase Warrant",
"Class B Common Stock Purchase Warrant",
"Form of Voting Agreement between NR-GRI Partners, LP, and each of the executive officers and directors of LENSAR, Inc"
05/15/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, between LENSAR, Inc. and NR-GRI Partners, LP",
"Registration Rights Agreement, between LENSAR, Inc. and NR-GRI Partners, LP"
05/15/2023 8-K Quarterly results
Docs: "LENSAR Reports First Quarter 2023 Results and Provides Business Update Increased ALLY® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded from LENSAR Laser System to ALLY Significantly strengthened balance sheet through $20 million private placement ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational initiatives. “I am thrilled with the growing momentum ALLY is ex..."
03/16/2023 8-K Quarterly results
Docs: "LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Installed ten ALLY® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. “The reception to our next generation ALLY System supports our confidence in this new technology and its potential to change th..."
02/14/2023 8-K Quarterly results
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2022 8-K Quarterly results
Docs: "LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update Company Launches ALLY™ Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update. “The third quarter was highlighted by the successful U.S. launch of the ALLY System during the week of August 15th, a pivotal corporate milestone, and the next important step in continuing the transition to our next generation system. We have installed multiple ALLY Systems in select sites with surgeons performing cases with th..."
09/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent U.S. commercial launch, this is another important step in our effort to bring ALLY to cataract surgeons in key global markets. Our mission has always been to create a platform that optimizes the way premium cataract surgeries are performed, and we believe that ALLY addresses all limitations of current competitive technologies.” said Nick Cur..."
08/16/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
01/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2021 8-K Quarterly results
Docs: "LENSAR, Inc."
08/05/2021 8-K Quarterly results
Docs: "LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels"
05/19/2021 8-K Submission of Matters to a Vote of Security Holders
05/05/2021 8-K Quarterly results
04/15/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2021 8-K Quarterly results
02/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : January 29, 2021 LENSAR, Inc. Delaware 001-039473 32-0125724 2800 Discovery Drive, Orlando, Florida 32826 536-7271 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ...",
"LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O'Farrell"
12/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2020 LENSAR, INC. Delaware 001-039473 32-0125724 2800 Discovery Drive, Orlando, Florida 32826 Registrant's telephone number, including area code: 536-7271 Not Applicable"
11/09/2020 8-K Quarterly results
Docs: "LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update"
10/02/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy